Marietta Wu

Director

Marietta Wu’s experience ranges from clinical medicine and medical research to finance and entrepreneurship. Prior to joining Burrill, Dr. Wu held professional positions with Edwards Lifesciences and Eli Lilly & Company. She was Director of Strategy at Edwards, responsible for the strategic planning in the biologics program. At Eli Lilly & Company Oncology and Integrated Biology, Dr. Wu oversaw finance, business development, pipeline valuation, organizational restructure, and outsourcing strategy. She also worked at Eli Lilly’s M&A Group and with Oncology Discovery Research. Dr. Wu founded BioHorizon, a consultancy focused on value creation in the life sciences industry across the Pacific Rim. She advised a number of biotech startups and venture capital firms. Dr. Wu also has leadership positions in several professional organizations promoting transpacific business initiatives, including serving as secretary-general for the BayHelix Group.

Dr. Wu’s scientific expertise centers on basic and clinical research in oncology and neuroscience. She was selected by Nobel Laureate Dr. Marshall Nirenberg as an IRTA Fellow at the National Institutes of Health. Dr. Wu received her M.D. from Shanghai Second Medical University, a Ph.D. in Medical Sciences with a focus in biochemistry and molecular biology from Medical College of Ohio, and an MBA from the University of Michigan Business School.